FDA Expands Indications for Neuraceq®, an Amyloid PET Imaging Agent, to Enhance Diagnosis and Care of Patients with Alzheimer's Disease

FDA Expands Indications for Neuraceq®, an Amyloid PET Imaging Agent, to Enhance Diagnosis and Care of Patients with Alzheimer's Disease

New indication added for selection of patients for amyloid-directed therapies

Post Hoc Analysis Highlights Brexpiprazole’s Efficacy and Tolerability in Alzheimer Agitation

As the first FDA-approved treatment for Alzheimer agitation, brexpiprazole showcased effective symptom relief with a favorable safety profile.